Lexicon Pharmaceuticals Inc LXRX:NASDAQ

Last Price$3.15NASDAQ Previous Close - Last Trade as of 4:00PM ET 1/21/22

Today's Change-0.10(3.08%)
Bid (Size)$3.10 (5)
Ask (Size)$3.15 (9)
Day Low / High$3.14 - 3.30
Volume530.5 K
 

View Biotechnology IndustryPeer Comparison as of 01/21/2022

 

Lexicon Pharmaceuticals Inc ( NASDAQ )

Price: $3.15
Change: -0.10 (3.08%)
Volume: 530.5 K
4:00PM ET 1/21/2022
 
 

Deciphera Pharmaceuticals Inc ( NASDAQ )

Price: $8.04
Change: -0.11 (1.35%)
Volume: 1.3 M
4:00PM ET 1/21/2022
 
 

BioXcel Therapeutics Inc ( NASDAQ )

Price: $16.68
Change: -0.75 (4.30%)
Volume: 462.7 K
4:00PM ET 1/21/2022
 
 

Chimerix Inc ( NASDAQ )

Price: $5.51
Change: -0.07 (1.25%)
Volume: 838.5 K
4:00PM ET 1/21/2022
 
 

VBI Vaccines Inc ( NASDAQ )

Price: $1.74
Change: -0.09 (4.92%)
Volume: 3.6 M
4:00PM ET 1/21/2022
 

Read more news Recent News

Lexicon Pharmaceuticals Eyes Heart Drug Sotagliflozin's US Launch in H2
1:31PM ET 1/13/2022 MT Newswires

Lexicon Pharmaceuticals (LXRX) said Thursday it plans to commercialize heart drug sotagliflozin in the US in H2 if the Food and Drug Administration...

MT Newswires After Hours Watch List: MDRR, LXRX
5:03PM ET 12/30/2021 MT Newswires

Here are some of the stocks moving in after-hours trading worth watching in Friday's regular session: MDRR:+33.3%; Approves share buyback plan; LXRX:...

Lexicon Pharmaceuticals Files New Drug Application For Treatment of Heart Failure in Diabetic Patients
4:16PM ET 12/30/2021 MT Newswires

Lexicon Pharmaceuticals (LXRX) late Thursday said that it has submitted a new drug application to the US Food and Drug Administration for sotagliflozin for...

Sector Update: Health Care Stocks Edge Higher Premarket Monday
9:14AM ET 11/15/2021 MT Newswires

Health care stocks were edging higher premarket Monday. The Health Care Select Sector SPDR ETF (XLV) was climbing by 0.31% while the iShares Biotechnology...

Company Profile

Business DescriptionLexicon Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. Its drug candidates include: LX9211, an orally-delivered small molecule drug candidate, as a treatment for neuropathic pain; and sotagliflozin, a treatment for heart failure and type 1 diabetes. The company was founded by Brian P. Zambrowicz and Arthur T. Sands on July 7, 1995 and is headquartered in The Woodlands, TX. View company web site for more details
Address2445 Technology Forest Boulevard
The Woodlands, Texas 77381-1160
Phone+1.281.863.3000
Number of Employees202
Recent SEC Filing01/10/20225
Chief Executive Officer & DirectorLonnel Coats
President & Chief Financial OfficerJeffrey L. Wade
Chief Medical Officer & Senior Vice PresidentCraig B. Granowitz
Secretary, Vice President & General CounselBrian T. Crum

Company Highlights

Price Open$3.24
Previous Close$3.25
52 Week Range$3.14 - 9.65
Market Capitalization$469.0 M
Shares Outstanding148.9 M
SectorHealth Technology
IndustryBiotechnology
Next Earnings Announcement03/09/2022

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / EarningsN/A
Earnings per Share-$0.48
Beta vs. S&P 500N/A
Revenue$63.2 M
Net Profit Margin-14,004.55%
Return on Equity-46.43%

Analyst Ratings as of 10/08/2021

Buy
1
Overweight
0
Hold
2
Underweight
0
Sell
0
Consensus RecommendationConsensus Icon
Powered by Factset